Jiabu Ye

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Han Si, Michael Kuziora, Katie Quinn et al. · Clinical Cancer Research · 2020 · 109 citations · Full text

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

Sriram Sridhar, Luis Paz‐Ares, Hao Liu et al. · Clinical Lung Cancer · 2019 · 58 citations · Full text

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · Journal of Thoracic Oncology · 2019 · 56 citations · Full text

Clinical Immunology, Immunogenetics, Autoimmune Disease +11

Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

Satrajit Roychoudhury, Keaven M. Anderson, Jiabu Ye et al. · Statistics in Biopharmaceutical Research · 2021 · 51 citations · Full text

Straw Man Proposal, Clinical Endpoint, Riskbenefit Ratio +19

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

Khader Shameer, Youyi Zhang, Dan Jackson et al. · Frontiers in Oncology · 2021 · 34 citations · Full text